BI 1356 BS in Japanese Patients With Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 1356
BS (0.5 mg, 2.5 mg, and 10 mg) administered orally once daily for 28 days in Japanese
patients with type 2 diabetes mellitus.